Prosper Akankwasa Mbbs,Jackson Kakooza Mbbs,Aisha Abdullahi Ahmed Mbbs et al.
Prosper Akankwasa Mbbs et al.
Adult granulosa cell tumor (GCT) of the ovary is a rare sex cord-stromal neoplasm characterized by potential for late recurrence. Hepatic metastases from GCT are exceedingly uncommon. We report a case of late hepatic relapse occurring 15 ye...
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology [0.03%]
癌症中的收敛和发散信号通路：适应性精准肿瘤学的双轴模型
Aliasgar Shahiwala PhD
Aliasgar Shahiwala PhD
Despite significant advances in cancer research, the complexity of signaling pathways remains a major challenge in precision oncology. Tumors harbor a diverse array of genetic alterations; however, these often converge onto a limited set of...
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva [0.03%]
外阴近端型上皮样肉瘤的诊疗进展与挑战
Fatimah M Kaabi Mbbs,Chaker Zaidi Md PhD,Fatimah Abdullah Alessa Mbbs et al.
Fatimah M Kaabi Mbbs et al.
Purpose: To present a rare case of proximal-type epithelioid sarcoma (PES) of the vulva and highlight the importance of a multidisciplinary approach in its diagnosis and treatment, especially in the context of SMARCB1 los...
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era [0.03%]
正电子发射断层扫描指导下经典型霍奇金淋巴瘤治疗进展（适应性治疗）
Wael Abdulla Moh Khair Md
Wael Abdulla Moh Khair Md
Interim fluorodeoxyglucose (FDG)-PET is currently the most used predictor of early response to treatment in advanced-stage Hodgkin lymphoma. Patients with a negative PET after 2 cycles of chemotherapy (PET2) have a better treatment outcome ...
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1-Positive Metastatic NSCLC [0.03%]
Trabedersen（OT-101）联合帕博利珠单抗治疗新诊断的PD-L1阳性转移性NSCLC患者：一项2期研究
Omar K Abughanimeh Mbbs,Anthony E Maida Iii PhD Ma Mba,Sanjive Qazi PhD et al.
Omar K Abughanimeh Mbbs et al.
Improving Leukoplakia Follow-Up: Information Leaflets, Habit Cessation Counseling [0.03%]
改进 leukoplakia 的随访：信息小册子和习惯戒除咨询
Shaila Mulki PhD Mds,Seema Mavinapalla Mds,Supriya Hulimane Mds et al.
Shaila Mulki PhD Mds et al.
Background: The rising incidence of oral cancer necessitates widespread implementation of preventive measures, particularly in resource-challenged settings where visual examination and patient education are more feasible....
Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features [0.03%]
罕见的具有非典型组织病理学特征的胶质母细胞瘤病例的分子特征分析
Nanuli Gvazava Md,Tolga Tuncer,Wei Zhang Md PhD et al.
Nanuli Gvazava Md et al.
A 76-year-old man presented with a subtle, non-mass-like right insular and temporal opercular T2 FLAIR hyperintensity that remained stable for over 2 years before showing interval progression. Resection revealed mildly hypercellular atypica...
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer [0.03%]
胰高糖素样肽-1受体激动剂的使用与乳腺癌患者的体重变化的关系
Sherry Shen,Bethina Liu Md,Chad Fanti Md et al.
Sherry Shen et al.
Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis; some breast cancer treatments contribute to postdiagnosis weight gain. We evaluated patients with breast cancer who were prescribed a glucagon-l...
Safeguarding Vulnerability: COVID-19's Impact on Immunocompromised Patients With Cancer [0.03%]
新冠肺炎疫情下的癌症免疫抑制患者：困境与保护
Viviana Cortiana Ms,Maduri Balasubramanian Md,Jade Gambill Bs et al.
Viviana Cortiana Ms et al.
The COVID-19 pandemic has exposed significant vulnerabilities among patients who are immunocompromised, who remain at increased risk for severe disease despite widespread vaccination in the general population. This commentary reviews insigh...
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment [0.03%]
揭秘zenocutuzumab潜力：NSCLC和胰腺癌治疗的突破性进展
Sanan Rasheed Mbbs,Umer Farooq Mbbs,Aiman Waheed et al.
Sanan Rasheed Mbbs et al.
Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective resp...